Insulet Corp (PODD) stock analysis

P/E below its 5-year median

Insulet's P/E of 24.4 is below its own 5-year median of 58.8.

P/E below the industry

Insulet's P/E of 24.4 is below the Surgical, Medical, and Dental Instruments and Supplies median of 27.7.

EV/EBITDA below its 5-year median

Insulet's EV/EBITDA of 15.6 is below its 5-year median of 51.8.

P/B above the industry

Insulet's price-to-book of 6.59 is above the Surgical, Medical, and Dental Instruments and Supplies median of 3.22.

Trading below fair value

The share price of $150.03 is below our fair value estimate of $279.33.

Margin of safety over 20%

The price is 46.3% below fair value, more than the 20% cushion we look for.

Revenue growing 10%+ a year

Revenue grew 27.5% a year over the last three fiscal years.

EPS growing 10%+ a year

Diluted EPS grew 268% a year over the last three fiscal years.

Earnings growth not accelerating

Net income grew 74.2% over the last twelve months, against a 5-year average of 105% a year.

Growing faster than the industry

Revenue grew 26.5% over the last twelve months; the Surgical, Medical, and Dental Instruments and Supplies median is 11.0%.

Guidance raised

Insulet raised its Q3 2026 Total outlook on Aug 5, 2026.

Gross margin improving

Gross margin was 71.9% over the last twelve months, against 71.5% a year earlier.

Return on equity over 15%

Return on equity was 28.9% over the last twelve months and averaged 19.8% over five years.

Return on capital over 10%

Return on invested capital was 25.5%, above the 10% that usually covers the cost of capital.

Return on equity above the industry

Insulet's return on equity of 28.9% is above the Surgical, Medical, and Dental Instruments and Supplies median of -31.3%.

Earnings grew over 5 years

Net income grew 105% a year on average over the last five fiscal years.

Net margin above its 5-year average

Net margin was 13.4% over the last twelve months, against a 5-year average of 8.7%.

Net margin above the industry

Insulet's net margin of 13.4% is above the Surgical, Medical, and Dental Instruments and Supplies median of -14.1%.

High debt

Debt is 60.9% of shareholders' equity, above the 40% we consider low.

Debt falling against equity

Debt to equity fell from 175% five years ago to 60.9%.

Debt covered by cash flow

Operating cash flow over the last twelve months equals 52.9% of total debt.

Interest well covered

Operating income covers interest expense 9.9 times.

Short-term assets cover short-term debts

Current assets are 2.51 times current liabilities.

Low bankruptcy risk

The Altman Z-score is 5.59; above 3 is the safe zone and below 1.8 the distress zone.

No dividend

Insulet has not paid a dividend in the last twelve months.

Yield against Treasuries

No dividend.

Yield against the market

No dividend.

Dividend stability

No dividend.

Earnings cover

No dividend.

Cash-flow cover

No dividend.